Envisagenics, a NYC-based Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured a Series A financing of undisclosed amount.
The round was led by Red Cell Partners, with participation from Microsoft’s M12, Madrona Venture Group, Third Kind Venture Capital, Dynamk Capital, and Empire State Development’s venture capital arm, New York Ventures. In conjunction with the funding, Grant Verstandig, co-founder of Red Cell Partners, and Alan S. Roemer will join Envisagenics’ Board of Directors.
The company intends to use the funds to scale its drug discovery platform and biopharmaceutical partnerships.
Led by co-founder and CEO Maria Luisa Pineda, PhD., and Martin Akerman, Ph.D., co-founder and CTO, Envisagenics conducts research and development that focuses on diseases that are caused in part by RNA splicing deregulation and have patient populations with significant unmet needs. Its principal proprietary technology, the SpliceCore® discovery platform, re-envisions the human genome through a validated, exon-centric approach combined with Machine Learning algorithms and high-performance computing. SpliceCore’s database is composed of approximately seven million RNA splicing events.
Envisagenics’ SpliceCore technology has been commercially validated by multiple biopharma leaders.